Key industry leaders will gather at the inaugural CRISPR Precision Gene Editing Congress with an ultimate purpose of addressing the importance of overcoming specificity, efficiency and delivery challenges associated with the CRISPR/Cas9 system. Pioneers will showcase the expanding biomedical and therapeutic potential of gene editing tools for drug discovery and development.
An Introduction to Crispr Genome EditingChris Thorne
In this short presentation, I make a case for doing genome editing vs some of the approaches that have gone before, describe some of the tools available, and the focus on CRISPR-Cas9, what it is, where it's come from and how it works.
The CRISPR/Cas9 system has emerged as one of the leading tools for modifying genomes of organisms ranging from E. coli to humans. Additionally, the simple gene targeting mechanism of CRISPR technology has been modified and adapted to other applications that include gene regulation, detection of intercellular trafficking, and pathogen detection. With a wealth of methods for introducing Cas9 and gRNAs into cells, it can be challenging to decide where to start. In this presentation, Dr Adam Clore describes the CRISPR mechanism and some of the most prominent uses for CRISPR, along with methods where IDT technologies can assist scientists in designing, testing, and executing a variety of CRISPR-mediated experiments. For more informaton, visit: http://www.idtdna.com/crispr
An Introduction to Crispr Genome EditingChris Thorne
In this short presentation, I make a case for doing genome editing vs some of the approaches that have gone before, describe some of the tools available, and the focus on CRISPR-Cas9, what it is, where it's come from and how it works.
The CRISPR/Cas9 system has emerged as one of the leading tools for modifying genomes of organisms ranging from E. coli to humans. Additionally, the simple gene targeting mechanism of CRISPR technology has been modified and adapted to other applications that include gene regulation, detection of intercellular trafficking, and pathogen detection. With a wealth of methods for introducing Cas9 and gRNAs into cells, it can be challenging to decide where to start. In this presentation, Dr Adam Clore describes the CRISPR mechanism and some of the most prominent uses for CRISPR, along with methods where IDT technologies can assist scientists in designing, testing, and executing a variety of CRISPR-mediated experiments. For more informaton, visit: http://www.idtdna.com/crispr
CRISPR-Cas9 is a unique technology that enables geneticists and medical researchers to edit parts of the genome by removing, adding or altering sections of the DNA sequence.
It is currently the simplest, most versatile and precise method of genetic manipulation and is therefore causing a buzz in the science world.
CRISPR is easily the best gene editing tool to date. For decades, scientists have been looking for a way to to perform precise changes to genetic sequences. In the past several years, researchers were able to exploit the immune systems of bacteria to edit the genome of other living cells. CRISPR is reported to have higher targeting efficiencies when compared to TALENs and Zinc Fingers. It is efficient, easy to use and cheap; making it a scalable genetic engineering tool that is highly desirable in various industry-wide applications.
Speaker: Benedict C. S. Cross, PhD, Team leader (Discovery Screening), Horizon Discovery
CRISPR–Cas9 mediated genome editing provides a highly efficient way to probe gene function. Using this technology, thousands of genes can be knocked out and their function assessed in a single experiment. We have conducted over 150 of these complex and powerful screens and will use our experience to guide you through the process of screen design, performance and analysis.
We'll be discussing:
• How to use CRISPR screening for target ID and validation, understanding drug MOA and patient stratification
• The screen design, quality control and how to evaluate success of your screening program
• Horizon’s latest developments to the platform
• Horizon’s novel approaches to target validation screening
CRISPR-Cas9 is a genome editing tool that is creating a buzz in the science world. It is faster, cheaper and more accurate than previous techniques of editing DNA and has a wide range of potential applications.
Genome Editing Comes of Age; CRISPR, rAAV and the new landscape of molecular ...Candy Smellie
Information is no longer a bottleneck, emphasis is shifting to the ‘what does it all mean’
In a translational context we hope that by answering that question we will be able to is to characterise the genetics that drive disease, and indeed develop drugs and diagnostics that are personalised to patients.
Genome editing provides the link between the information here, and this outcome here, by allowing scientists to recapitulate specific genetic alterations in any gene in any living tissue to probe function, develop disease models and identify therapeutic strategies. So, not only do we now have unparalleled access to genetic information, but we now have the tools to most accuartely understand what this genetic information – with genome editing allowing us to explore the genetic drivers of disease in physiological models.
AAV is a single-stranded, linear DNA virus with a a 4.7 kb genome which for the purpose of genome editing is replaced almost in entirety with the targeting vector sequence (except for the iTRs)
It is in effect a highly effective DNA delivery mechanism
After entry of the vector into the cell, target-specific homologous DNA is believed to activate and recruit HR-dependent repair factors can induce HR at rates approximately 1,000 times greater than plasmid based double stranded DNA vectors, but the mechanism by which it achieves this is still largely unknown
By including a selection cassette can select for cells that have integrated the targeting vector, and then screen for clones which have undergone targeted insetion rather than random integration, which will generally be around 1%.
A New molecular biology techniques for gene therapyVanessa Chappell
The CRISPR (clustered, regularly interspaced, short palindromic repeats)-Cas9 (CRISPR-associated protein 9) system is a targeted nuclease technology which allows precise genome editing. Since the discovery of this system there has been great interest in its potential for human gene therapy. The CRISPR-Cas9 system has many advantages in comparison to other targeted nucleases transcription activator-like effector nucleases and zinc finger nucleases. As a relatively new genome editing platform, safety issues such as off-target editing have yet to be fully investigated.This presentation addresses the challenges as well as the socio-ethical considerations that surround the use of human genome editing.
2nd CRISPR Congress Boston, 23-25 February 2016 Diane McKenna
The 2nd Annual CRISPR Congress will enhance the basic research, drug discovery and therapeutic applications of CRISPR technology by overcoming key specificity, efficiency and delivery challenges needed to improve the precise editing and repair of the genome.
As a leading provider of gene editing service, Creative Biogene has launched a powerful CRISPR/Cas9 Platform. Our platform performs gene knockout/knockin programme with CRISPR/Cas9 system, from designing gRNA constructs to transfection and single clone generation of a wide range of cells, including difficult-to-transfect and tumor cell lines, as well as plants, mouse and other animal models.
CRISPR is a new mechanism\tool to edit genes and in coming future it will provide us many new levels of success in curing of genetic disorders and modifying genes for human benifit
hydrogen water generator information氢化水Hannas Chen
New Technology Hydrogen water Generator (from japan)
Hydrogen water is a strong antioxidant with high reduction potential to neutralize and prevent the harmful oxidative effects of free radicals. It also has micro-clustered water structure for superior hydration.
CRISPR-Cas9 is a unique technology that enables geneticists and medical researchers to edit parts of the genome by removing, adding or altering sections of the DNA sequence.
It is currently the simplest, most versatile and precise method of genetic manipulation and is therefore causing a buzz in the science world.
CRISPR is easily the best gene editing tool to date. For decades, scientists have been looking for a way to to perform precise changes to genetic sequences. In the past several years, researchers were able to exploit the immune systems of bacteria to edit the genome of other living cells. CRISPR is reported to have higher targeting efficiencies when compared to TALENs and Zinc Fingers. It is efficient, easy to use and cheap; making it a scalable genetic engineering tool that is highly desirable in various industry-wide applications.
Speaker: Benedict C. S. Cross, PhD, Team leader (Discovery Screening), Horizon Discovery
CRISPR–Cas9 mediated genome editing provides a highly efficient way to probe gene function. Using this technology, thousands of genes can be knocked out and their function assessed in a single experiment. We have conducted over 150 of these complex and powerful screens and will use our experience to guide you through the process of screen design, performance and analysis.
We'll be discussing:
• How to use CRISPR screening for target ID and validation, understanding drug MOA and patient stratification
• The screen design, quality control and how to evaluate success of your screening program
• Horizon’s latest developments to the platform
• Horizon’s novel approaches to target validation screening
CRISPR-Cas9 is a genome editing tool that is creating a buzz in the science world. It is faster, cheaper and more accurate than previous techniques of editing DNA and has a wide range of potential applications.
Genome Editing Comes of Age; CRISPR, rAAV and the new landscape of molecular ...Candy Smellie
Information is no longer a bottleneck, emphasis is shifting to the ‘what does it all mean’
In a translational context we hope that by answering that question we will be able to is to characterise the genetics that drive disease, and indeed develop drugs and diagnostics that are personalised to patients.
Genome editing provides the link between the information here, and this outcome here, by allowing scientists to recapitulate specific genetic alterations in any gene in any living tissue to probe function, develop disease models and identify therapeutic strategies. So, not only do we now have unparalleled access to genetic information, but we now have the tools to most accuartely understand what this genetic information – with genome editing allowing us to explore the genetic drivers of disease in physiological models.
AAV is a single-stranded, linear DNA virus with a a 4.7 kb genome which for the purpose of genome editing is replaced almost in entirety with the targeting vector sequence (except for the iTRs)
It is in effect a highly effective DNA delivery mechanism
After entry of the vector into the cell, target-specific homologous DNA is believed to activate and recruit HR-dependent repair factors can induce HR at rates approximately 1,000 times greater than plasmid based double stranded DNA vectors, but the mechanism by which it achieves this is still largely unknown
By including a selection cassette can select for cells that have integrated the targeting vector, and then screen for clones which have undergone targeted insetion rather than random integration, which will generally be around 1%.
A New molecular biology techniques for gene therapyVanessa Chappell
The CRISPR (clustered, regularly interspaced, short palindromic repeats)-Cas9 (CRISPR-associated protein 9) system is a targeted nuclease technology which allows precise genome editing. Since the discovery of this system there has been great interest in its potential for human gene therapy. The CRISPR-Cas9 system has many advantages in comparison to other targeted nucleases transcription activator-like effector nucleases and zinc finger nucleases. As a relatively new genome editing platform, safety issues such as off-target editing have yet to be fully investigated.This presentation addresses the challenges as well as the socio-ethical considerations that surround the use of human genome editing.
2nd CRISPR Congress Boston, 23-25 February 2016 Diane McKenna
The 2nd Annual CRISPR Congress will enhance the basic research, drug discovery and therapeutic applications of CRISPR technology by overcoming key specificity, efficiency and delivery challenges needed to improve the precise editing and repair of the genome.
As a leading provider of gene editing service, Creative Biogene has launched a powerful CRISPR/Cas9 Platform. Our platform performs gene knockout/knockin programme with CRISPR/Cas9 system, from designing gRNA constructs to transfection and single clone generation of a wide range of cells, including difficult-to-transfect and tumor cell lines, as well as plants, mouse and other animal models.
CRISPR is a new mechanism\tool to edit genes and in coming future it will provide us many new levels of success in curing of genetic disorders and modifying genes for human benifit
hydrogen water generator information氢化水Hannas Chen
New Technology Hydrogen water Generator (from japan)
Hydrogen water is a strong antioxidant with high reduction potential to neutralize and prevent the harmful oxidative effects of free radicals. It also has micro-clustered water structure for superior hydration.
Apollo is a web-based application that supports and enables collaborative genome curation in real time, allowing teams of curators to improve on existing automated gene models through an intuitive interface. Apollo allows researchers to break down large amounts of data into manageable portions to mobilize groups of researchers with shared interests.
An introduction on gene annotation & curation for the IAGC and BIPAA research communities.
Healthcare, Science & Education - Presentation by Jessica Federer, Head of Digital Development of Bayer at the Axel Springer NOAH Conference Berlin 2016, Tempodrom on the 9th of June 2016.
The CRISPR/Cas9 system has emerged as one of the leading tools for modifying the genomes of organisms ranging from E. coli to humans. In this presentation, we discuss various methods for generating the crRNA and tracrRNA components that are required for guiding the Cas9 endonuclease to genomic targets. You will also learn how to optimize a new 2-part CRISPR RNA system from IDT that offers multiple benefits over other technologies.
Apollo is a web-based application that supports and enables collaborative genome curation in real time, allowing teams of curators to improve on existing automated gene models through an intuitive interface. Apollo allows researchers to break down large amounts of data into manageable portions to mobilize groups of researchers with shared interests.
An introduction to use and functionality for the IAGC and BIPAA research communities.
2nd CRISPR Congress Boston, 23-25 February 2016 Diane McKenna
The 2nd Annual CRISPR Congress will enhance the basic research, drug discovery and therapeutic applications of CRISPR technology by overcoming key specificity, efficiency and delivery challenges needed to improve the precise editing and repair of the genome.
Updated Agenda- CRISPR Congress in Berlin, 24-26 October 2016Diane McKenna
The Only Industry Event Solely Dedicated to Optimising the Applications CRISPR Precision Genome Editing in Europe.
Overcome key specificity, efficiency & delivery challenges to pioneer drug discovery, biomedical research and therapeutic applications of precision genome engineering. With customisation of CRISPR design paramount, join leading biopharma and academic figureheads as they reveal advanced methodology, strategies and clinical timelines to fulfil the revolutionary promise of precision genome editing.
2nd CRISPR Precision Genome Editing congress Berlin 2017 AgendaDiane McKenna
2nd CRISPR Europe Congress is back with the key technology and industry developments uncovering more innovative applications. From basic research to therapeutic development, this end to end CRISPR Congress in Berlin will optimise your CRISPR workflow. Fully experience the value of this technology in base editing, primary cell editing, in vivo delivery, antiviral drugs & gene therapies.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Global Engage is pleased to announce the 2018 Precision Medicine & Biomarkers Leaders Summit USA taking place on May 7-8th in Boston, MA. The event is part of our highly successful Drug Discovery Series which includes conferences on Biologics, Medicinal Chemistry, NASH, Pharmaceutical R&D IT and the Human Microbiome amongst others. It is also the sister meeting of the European Precision Medicine Summit which has run successfully since 2013.
5th Tumor Models Boston July 2017 BrochureDiane McKenna
Tumor Models Boston 2017 will address the preclinical & clinical developments of the most promising therapies including targeted therapies, check-point inhibitors & CAR-T therapies and how these findings can be utilized to bridge the gap between preclinical and clinical studies.
Join us in Boston this coming Fall to attend Cambridge Healthtech Institute's (CHI) 2nd Annual FAST: Functional Analysis & Screening Technologies Congress on November 17-19, 2014 and meet with a community of 250+ biologists, screening managers, assay developers, engineers and pharmacologists dedicated to improving in vitro cell models and phenotypic screening to advance drug discovery and development at 6 conferences: Phenotypic Drug Discovery (Part I & II), Engineering Functional 3D Models, Screening and Functional Analysis of 3D Models, Organotypic Culture Models for Toxicology and Physiologically-Relevant Cellular Tumor Models for Drug Discovery. Delegates have the opportunity to share insights in interactive panel discussions and connect during networking breaks. View innovative technologies and scientific research revolutionizing early-stage drug discovery in the exhibit/poster hall.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
Discovery on Target 2014 - The Industry's Preeminent Event on Novel Drug TargetsJaime Hodges
Cambridge Healthtech Institute's 12th Annual Discovery on Target will showcase current and emerging “hot” targets for the pharmaceutical industry, October 8 – 10, 2014 in Boston, MA. Spanning three days, the meeting will bring together more than 900 global attendees, including scientists/technologists, executives, directors, and managers from biopharma, academic, and healthcare organizations. In 2014 the event is comprised of 14 conference tracks which include Epigenetic Readers, Ubiquitin Proteasome, Big Data Discovery, GPCR Drug Discovery, RNAi-Screens-Functional-Genomics, PPI Targets, Protein-Targets, Histone-Methyltransferases-Demethylases, Drug Transporters, Maximizing Efficiency, GPCR Therapeutics, Genomics Screening, Cancer Metabolism and Membrane Production. The 2014 event will offer 200+ scientific presentations across 14 conference tracks, 1 Symposium and 15 conference short courses, 40+ interactive breakout discussion groups, an exhibit hall of 40+ companies, and dedicated poster viewing and networking sessions.
CRISPR Agbio San Diego April 2017 AgendaDiane McKenna
CRISPR AgBio Congress is the first and only end-to-end meeting dedicated to helping agricultural biotech ad agrochemical companies leverage the power of CRISPR/Cas9 advanced trait breeding technology and precision genome editing, to overcome productivity challenges, increase yield and pioneer sustainable agriculture in plants breeding, crop protection and livestock. Commercialize the next generation of sustainable and superior agricultural products and help meet the world’s growing food demands.
Discover new cases studies giving you unprecedented access to both the data and results of how RNA-Seq is being applied successfully from bench to bedside
Gain new insights into RNA-Seq for the study of toxicity, IO, host-viral interactions and more from companies such as BMS, Janssen, Pfizer, Merck, UCSC and Stanford
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
This expanding series attracts the leading authorities worldwide working in companion diagnostics, biomarkers, immuno-oncology, liquid biopsies, AI and other facets of precision medicine. It has been praised for its stimulating, interactive and engaging environment where it brings together a multi-disciplined community of researchers, leaders and innovators whose aim is to develop groundbreaking and impactful treatments for patients.
Dr. Dennis Wang discusses possible ways to enable ML methods to be more powerful for discovery and to reduce ambiguity within translational medicine, allowing data-informed decision-making to deliver the next generation of diagnostics and therapeutics to patients quicker, at lowered costs, and at scale.
The talk by Dr. Dennis Wang was followed by a panel discussion with Mr. Albert Wang, M. Eng., Head, IT Business Partner, Translational Research & Technologies, Bristol-Myers Squibb.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Tracks focus on R&D strategies, Biomarker development, Immuno-oncology, CDx development, AI and Big data analysis and approaches – Attending this Summit will provide you with the opportunity to mix and interact with experts working in all facets of Precision Medicine through the individual, panel and roundtable discussions on offer.
Next Generation Dx Summit 2015 - Moving Assays to the ClinicJames Prudhomme
The Next Generation Dx Summit, entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year’s expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement. With widespread coverage of all the most relevant diagnostics topics, the Next Generation Dx Summit promises to be a must-attend event to hear the latest announcements and developments in this rapidly evolving field.
Seventh Annual Next Generation Dx SummitJaime Hodges
The Next Generation Dx Summit (www.nextgenerationdx.com), entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year’s expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement. With widespread coverage of all the most relevant diagnostics topics, the Next Generation Dx Summit promises to be a must-attend event to hear the latest announcements and developments in this rapidly evolving field.
Similar to CRISPR Gene Editing Congress, 25-27 February 2015 in Boston, MA (20)
Tumour models London 1-3 December 2015 AgendaDiane McKenna
Tumour Models London 2015, now in its 4th year,is the leading meeting dedicated to improve preclinical predictability and translational success of oncology discoveries. Tackling clinical failures rates, preclinical strategies and translational challenges, this Summit will enable you to translate your discoveries from model to human studies with superior predictability to future proof clinical success. [Read More…]
RNA-Seq Boston (23-25 June 2015) AgendaDiane McKenna
RNA-Seq Boston 2015 will enable scientists to overcome the data bottleneck by applying the most appropriate bioinformatics tools and develop a unified, integrated approach for analysis and interpretation of huge data sets, which in turn can positively impact therapeutic and clinical developments.
miRNA World, Boston, MA 28-30 October 2014Diane McKenna
miRNA World 2014 has been designed to take advantage of the explosion in miRNA research to harness the potential of these non-coding RNA’s.
With developments and advancements occurring all the time, miRNA World 2014 finds itself at the forefront of miRNA research and development.
Designed and constructed to harness the potential of miRNAs in a variety of research arenas, miRNA World 2014 will help maximize the therapeutic potential locked in these unique non-coding regions of the genome.
A meeting dedicated to engagement, collaboration and networking, miRNA World 2014 will address and discuss critical topics in the sector, including, miRNA biomarkers inside and outside of cancer, miRNA’s as diagnostics with particular focus on exosomal markers, the delivery, and pharmacological and efficacy challenges associated with both miRNA Mimics and Anti-miR’s.
2nd RNA-Seq, Boston, MA 17-19 June 2014 updated brochureDiane McKenna
-An overview of RNA-Seq field and look at new technologies
-RNA-Seq Sample Preparation
-RNA-Seq Strategies in Precision Medicine
-Panel Discussion Where are we with RNA-Seq Technology
-The Data: What are our options?
-Panel discussion: Dealing with the data
Applying Innovative RNA-Seq Technology to Support Research & Drug Discovery
Informatics & Statistical Analysis of RNA-Seq Data
Transcriptomics: Microarray vs RNA-Seq
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
CRISPR Gene Editing Congress, 25-27 February 2015 in Boston, MA
1. 25-27 February 2015 | Boston, USA
Tel: +1 212 531 5898 | Email: info@hansonwade.com
RESEARCHED & DEVELOPED BY:
Unlocking Precision Genome Editing for
Therapeutic Development & Biomedical
Research Applications
GEORGE CHURCH
Harvard University
ALEXANDRA GLUCKSMANN
Editas Medicine
ERIC RHODES
Horizon Discovery
KEITH JOUNG
Harvard University
RODGER NOVAK
CRISPR Therapeutics
This is
designed to
describe the
profound
impact CRISPR
is having on
basic research
and therapeutic
development. It
will explore the
research tools,
bioinformatics
and expertise
needed to make
the most of this
breakthrough
technology
Eric Rhodes on
CRISPR Congress 2015
crispr-congress.com
LEAD PARTNER PROGRAM PARTNERS EXHIBITORHOSTING PARTNER
2. 1 6
3 8
2 7
4 9
5 10
BENEFITS OF ATTENDING
Tel: +1 212 531 5898 Email: info@hansonwade.com
crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing
CRISPR Precision Gene Editing Congress
Boston, USA | 25-27 February 2015
Enhance the Implementation of CRISPR Gene
Editing Technology & Advance your Research
Seize the value of CRISPR/Cas9 gene editing and discover its evolving
application in target identification and therapeutic development
With its ground breaking convenience and simplicity, the
emergence of CRISPR genome technology has taken
gene editing from a niche pursuit and opened it up to
the wider scientific community, in turn revolutionizing
and optimizing the application of highly precise genome
editing.
Key industry leaders will gather at the inaugural CRISPR
Precision Gene Editing Congress with an ultimate
purpose of addressing the importance of overcoming
specificity, efficiency and delivery challenges associated
with the CRISPR/Cas9 system. Furthermore, pioneers
will showcase the exploding biomedical and therapeutic
potential of gene editing tools for drug discovery and
development.
CRISPR congress brings together those who are striving
to unlock the potential and capture the innovative
applications of CRISPR technology under one roof.
Utilize the industry’s greatest minds to optimize your
gene engineering applications.
Discover the approaches being applied to
overcome CRISPR/Cas9 off-cuts and enhance
specificity
Harness the bioinformatic approach to detect
off-cuts and improve CRISPR/Cas9 specificity
TOP 10 REASONS TO ATTEND CRISPR CONGRESS
Harness the innovative approaches being utilized
to overcome in vivo delivery challenges in the
development of disease models
Explore how CRISPR based functional
genomic screening is being applied to improve
identification and validation of new drug
targets
Explore how CRISPR technology is being
utilized in basic research to enhance your own
application of CRISPR gene editing
Discover how CRISPR technology is being
applied to compliment other gene editing tools
Learn about the application of CRISPR
technology in epigenome editing of human cells
and stem cell biology
Harness the high throughout methods being
developed for efficient RNA delivery and gene
editing
Enhance your knowledge on key safety issues
surrounding the development of CRISPR-based
therapeutics
Learn about the platform advancements
required to advance CRISPR technology to the
clinic and develop CRISPR-based therapies
3. SPEAKER FACULTY
Tel: +1 212 531 5898 Email: info@hansonwade.com
crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing
CRISPR Precision Gene Editing Congress
Boston, USA | 25-27 February 2015
Eric Rhodes
Chief Technology Officer
Horizon Discovery
Katrine Bosley
Chief Executive Officer
Editas Medicine
Keith Joung
Associate Chief of Pathology for
Research and the Jim and Ann
Orr MGH Research Scholar,
Massachusetts General Hospital;
Associate Professor of Pathology,
Harvard University
Alexandra Glucksmann
Chief Operating Officer
Editas Medicine
Matthew Porteus
Associate Professor of
Paediatrics
Stanford University
Charles Gersbach
Assistant Professor, Biomedical
Engineering, Investigator, Center
for Genomic and Computational
Biology
Duke University
Daniel Anderson
Sam Goldblith Associate
Professor
Massachusetts Institute
of Technology (MIT)
David Bumcrot
Senior Director, Molecular
and Cell Biology
Editas Medicine
Mark Kay
Professor of Pediatrics and
Genetics
Stanford University
Yi Yang
Senior Research Investigator
Novartis
Kiran Musunuru
Assistant Professor, Stem Cell
and Regenerative Biology
Harvard University
Stanley Qi
Assistant Professor,
Bioengineering and
Chemical and Systems
Biology
Stanford University
Gregory Davis
R&D Manager, Molecular
Biotechnology
Sigma-Aldrich
Corporation
Jason Potter
Senior Scientist in Protein
Engineering
Thermo Fisher Scientific
TJ Cradick
Director of Protein
Engineering Facility
Georgia Institute of
Technology
David Liu
Professor of Chemistry and
Chemical Biology, Howard
Hughes Medical Institute
Investigator
Harvard University
Wenning Qin
Associate Director of Genetic
Engineering Technologies
The Jackson Laboratory
Richard Chen
Principal Scientist, Genetics
and Pharmacogenomics
Merck
Rodger Novak
Chief Executive Officer
CRISPR Therapeutics
Terence Flotte
Professor, Dean
and Provost,
University of Massachusetts
Medical School
Derrick Rossi
Assistant Professor, Stem Cell and
Regenerative Biology
Harvard University
Christian Mueller
Assistant Professor,
Paediatrics
University of
Massachusetts
Medical School
John Feder
Associate Director of
Genome Biology
Bristol-Myers Squibb
Hari Jayaram
Senior Scientist
Editas Medicine
Jochen Welcker
Senior Manager Scientific
Development
Taconic Biosciences GmbH
VittorioSebastiano
AssistantProfessorofObstetrics
andGynecology,DirectorofHuman
PluripotentStemCellsCoreFacility
andTKTC
StanfordCancerInstitute
George Church
Professor of Genetics
Harvard Medical School
4. CONFERENCE DAY ONE
8.00 Registration, Breakfast & Networking
9.00 Welcome Address from Lead Partner Horizon Discovery Eric Rhodes, Chief Technology Officer, Horizon Discovery
9.05 Chair’s Opening Remarks
Alexandra Glucksmann, Chief Operating Officer,
Editas Medicine
9.10 Unlocking Future CRISPR Applications: Conversations
That Matter
Gain an exclusive insight into the latest developments within the field of CRISPR
technology via one-on-one interviews with a panel of key opinion leaders. Join those
paving the way in implementing CRISPR technology for therapeutic and biomedical
applications, as well as in drug discovery and development. The panel will discuss and
answer the following questions:
• Are we in a CRISPR revolution?
• What has been the impact so far and how high can CRISPR reach?
• How can we make this technology better and work harder?
• What are the potential applications of CRISPR in drug discovery and development?
• How is the technology being utilized for gene therapy?
Moderator: Alexandra Glucksmann, Chief Operating
Officer, Editas Medicine
Keith Joung, Associate Chief of Pathology for Research
and the Jim and Ann Orr MGH Research Scholar,
Massachusetts General Hospital; Associate Professor
of Pathology, Harvard University
Rodger Novak, Chief Executive Officer, CRISPR
Therapeutics
Charles Gersbach, Assistant Professor, Department of
Biomedical Engineering, Investigator, Center for Genomic
and Computational Biology, Co-Director, Center for
Biomolecular and Tissue Engineering, Duke University
Katrine Bosley, Chief Executive Officer, Editas Medicine
10.00 CRISPR and the Rapidly Changing Landscape of Genome
Editing
• Learnings accumulated from over 1 year of industrial application of CRISPR to
in vitro and in vivo genome editing. Incorporation of CRISPR into products, services
and research programs that enable customers engaged at every stage of the
healthcare continuum
• Harnessing gene editing of haplogenic cell lines
• A bioinformatics approach for CRISPR experimental design
Eric Rhodes, Chief Technology Officer, Horizon Discovery
Horizon welcome’s their partners:
Tilmann Burckstummer, Director Research and
Development, Horizon Genomics GmbH
Riley Doyle, Chief Executive Officer,
Desktop Genetics Ltd
10.30 Morning Refreshments & Speed Networking
Harnessing CRISPR Technology for Epigenome Editing
11.30 Optimizing Technologies for CRISPR-Based Targeted
Genome and Epigenome Editing of Human Cells
• Harness the latest advances in the technologies for highly efficient CRISPR-based
genome editing of human cells
• Learn about the innovative approaches in CRISPR-mediated epigenome editing of
human cells
Keith Joung, Associate Chief of Pathology for
Research and the Jim and Ann Orr MGH Research
Scholar, Massachusetts General Hospital; Associate
Professor of Pathology, Harvard University
12.30 Genome and Epigenome Modification with ZFNs and
CRISPR/Cas Systems
• CRISPR nuclease and highly specific paired nickase formats for genome editing in
animal and plant cells
• Donor DNA formats and their impact on DNA repair rates
• New experimental possibilities using lentiviral delivery of CRISPR elements and
CRISPR-based screening
• Zinc finger and CRISPR-mediated epigenetic modifications
Gregory Davis, R&D Manager, Molecular
Biotechnology, Sigma-Aldrich Corporation
1.00 Networking Lunch & Speakers’ Corner
2.00 Epigenome Editing and Controlling Cell Phenotype
• Utilizing CRISPR/Cas9-based epigenome editors which are exceptionally specific with
regards to genome-wide DNA-binding, gene regulation, and chromatin remodeling
• Discover how gene network activation by CRISPR/Cas9-based epigenome editors can
be used to reprogram cell phenotype and drive pluripotent cell differentiation
• Harness these enhanced strategies for disease modeling, drug screening and
potentially regenerative medicine
Charles Gersbach, Assistant Professor, Department
of Biomedical Engineering, Investigator, Center for
Genomic and Computational Biology, Co-Director,
Center for Biomolecular and Tissue Engineering, Duke
University
Tel: +1 212 531 5898 Email: info@hansonwade.com
crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing
CRISPR Precision Gene Editing Congress
Boston, USA | 25-27 February 2015
Wednesday 25th February 2015 Keynote Session Interactive Session Networking Session
5. The Discovery & Implementation of CRISPR Technology in Innovative Applications
2.30 Genome Editing Tools and Workflows to Address Cell
Engineering Needs
• Utilising the Cas9 protein or cas9 mRNA
• Cationic lipid mediated transfection or electroporation workflows
• Developing up to 95% single knock outs in difficult cell lines
• High efficiencies for bi-allelic multiplex knock out
Jason Potter, Senior Scientist in Protein Engineering,
Thermo Fisher Scientific
3.00 Genome Editing to Dissect the Role of Retroviral lnCRNAs
in Human Development
• Overview of lncRNAs of retroviral origin in human and primates
• Role of lncRNAs in human pluripotent cells
• Genome editing in diverse embryonic cell types and functional characterization on
one specific lncRNA
Vittorio Sebastiano, Assistant Professor of Obstetrics
and Gynecology, Director of Human Pluripotent Stem
Cells Core Facility and Transgenic, Knockout and
Tumor Model Center (TKTC), Stanford Cancer Institute
3.30 Ultra-Sensitive Quantification of Genome Editing Events
by Droplet Digital PCR
• Genome editing events are rare, with NHEJ and HDR allele frequencies often <5%
in targeted cell populations
• Locus-specific quantification of NHEJ versus HDR alleles is emerging as an
important readout for optimizing genome-editing protocols
• Here we describe the use of droplet digital PCR (ddPCR) for ultra-sensitive
absolute quantification of NHEJ and HDR alleles in edited samples
Jennifer Berman , Staff Scientist, Applications, Digital
Biology Center, Bio-Rad Laboratories
4.00 Afternoon Refreshments & Poster Session
4.30 Technologies and Applications Enabled by CRISPR-
Mediated Gene Regulation
• Establishing technologies for targeted gene regulation using a nuclease deficient
CRISPR system
• Development of CRISPR technology for different goals of gene regulation such
as activation or repression, known as CRISPR interference (CRISPRi) or CRISPR
activation (CRISPRa)
• Applications of CRISPRi/a for drug target characterization, cell engineering, and
genome-wide screenings
Stanley Qi, Assistant Professor, Bioengineering and
Chemical and Systems Biology, Stanford University
5.00 Interactive CRISPR Mastermind
The CRISPR speaker faculty is second to none but there is just as much knowledge
in the audience as there is onstage. Tap into the wealth of perspectives on key issues
during interactive discussions, specifically designed so you can learn from fellow peers
and CRISPR experts. Drive your own learning, crowd-source ideas and get inspired!
1. What are the current approaches being utilized for enhancing CRISPR specificity -
overcoming off-target challenges?
2. How to overcome delivery challenges within genome editing
3. Utilizing CRISPR technology for modeling disease: How CRISPR technology
can be best applied to convert human GWAS/whole genome sequencing data from
“association” to “causation”?
4. How to use a bioinformatic approach for enhancing CRISPR applications
5. What challenges need to be addressed to establish safety models for gene therapy?
MODERATED BY:
Keith Joung, Associate Chief of Pathology for Research
and the Jim and Ann Orr MGH Research Scholar,
Massachusetts General Hospital; Associate Professor
of Pathology, Harvard University
David Liu, Professor of Chemistry and Chemical
Biology, Howard Hughes Medical Institute Investigator,
Harvard University
David Bumcrot, Senior Director, Molecular and Cell
Biology, Editas Medicine
Richard Chen, Principal Scientist, Genetics and
Pharmacogenomics, Merck
Matthew Porteus, Associate Professor of Paediatrics,
Stanford University
John Feder, Associate Director of Genome Biology,
Bristol-Myers Squibb
5.50 Chair’s Closing Remarks
Alexandra Glucksmann, Chief Operating Officer,
Editas Medicine
6.00 Close of Day 1
6.10 Evening Drinks Reception Hosted by Horizon Discovery
Tel: +1 212 531 5898 Email: info@hansonwade.com
crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing
CRISPR Precision Gene Editing Congress
Boston, USA | 25-27 February 2015
Keynote Session Interactive Session Networking Session
CONFERENCE DAY ONE - CONTINUED
Wednesday 25th February 2015
6. Tel: +1 212 531 5898 Email: info@hansonwade.com
crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing
CRISPR Precision Gene Editing Congress
Boston, USA | 25-27 February 2015
CONFERENCE DAY TWO
8.00 Breakfast & Networking
9.00 Chair’s Opening Remarks
CRISPR State of Address- What can we take forward from the discussions so far?
Eric Rhodes, Chief Technology Officer, Horizon Discovery
Overcoming the Main CRISPR Technology Hurdles: Specificity & Delivery
9.10 Nucleic Acid Delivery Systems for RNA Therapy and Gene
Editing
• To discuss the high throughput methods for developing and characterizing RNA
delivery and gene editing systems
• Developing delivery formulations with in vivo efficacy, and show potential
therapeutic application for the treatment of genetic disease, viral infection, and
cancer
Daniel Anderson, Sam Goldblith Associate Professor,
Massachusetts Institute of Technology (MIT)
9.40 Bioinformatics for Testing and Improving CRISPR
Specificity
• Harnessing bioinformatics for the determination of possible off-target cleavage
sites
• Developing assays for off-target cleavage events
TJ Cradick, Director of Protein Engineering Facility,
Georgia Institute of Technology
10.10 From “Gene Editing” to True Genome-Scale
Engineering”
• Reducing issues with competing events like Non-Homologous End-Joining
(NHEJ) and efficiency of large construct insertion/replacements in homologous
recombination editing
• Overcoming NHEJ events with the use of a promising alternative to double-strand
breaks (CRISPR, dual nickase or FokI) via recombinase/integrase mechanisms
George Church, Professor of Genetics, Harvard
Medical School
10.40 Morning Refreshments & Networking
11.00 Increasing the Therapeutic Relevance of CRISPR
Technologies to Address Delivery and Specificity
Challenges
• Discover the successful engineering of TALEN and Cas9 variants with greatly
improved specificity
• Harness a new approach to the delivery of proteins that has enabled the highly
potent, non-endosomal delivery of genome-editing proteins into mammalian cells
David Liu, Professor of Chemistry and Chemical
Biology, Howard Hughes Medical Institute Investigator,
Harvard University
12.00 Bioinformatic Approaches to Optimize Guide-RNA Design
and Assay Cas9 Specificity
• Explore the various algorithms and tools to assist in design of guide-RNAs for
Cas9 mediated gene editing
• Explore formats to standardize reporting of CRISPR mediated gene editing
experiments
Hari Jayaram, Senior Scientist, Editas Medicine
12.30 Networking Lunch
Application of CRISPR in Disease Modeling & Drug Screening
1.30 Interrogation of Novel Genes and Loci in Cardiovascular
Diseases with CRISPR Genome Editing
• Utilizing CRISPR to interrogate novel genes identified by genomic studies of
cardiovascular disease
• Implementing CRISPR to generate reporter cell lines for functional and drug
screens
Kiran Musunuru, Assistant Professor, Stem Cell and
Regenerative Biology, Harvard University
2.00 CRISPR/Cas-Mediated Genome Engineering in Mice with
High Efficiency and Throughput
• Significantly improving the efficiency of CRISPR/Cas-mediated insertion of a
transgene into an endogenous locus through pronuclear injection into zygotes
• Using whole genome sequencing to comprehensively characterized the off-target
effect of CRISPR/Cas9 targeting the Nanog locus
Wenning Qin, Associate Director of Genetic
Engineering Technologies, The Jackson Laboratory
Thursday 26th February 2015 Keynote Session Interactive Session Networking Session
7. Tel: +1 212 531 5898 Email: info@hansonwade.com
crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing
CRISPR Precision Gene Editing Congress
Boston, USA | 25-27 February 2015
2.30 Therapeutic Genome Editing in Human Hematopoietic
Stem Cells using CRISPR/Cas9 Technology
• Harnessing CRISPR/Cas9 technology for applying genome editing in human
hematopoietic stem cells
• How the CRISPR/Cas9 system can be used to achieve very high on-target and very
low off-target mutagenesis in human CD34+ human hematopoietic stem cells
Derrick Rossi, Assistant Professor, Stem Cell and
Regenerative Biology, Harvard University
3.00 Rapid Generation of Mouse and Rat Mutants by CRISPR/
Cas in One-Cell Embryos
• Experiences from the implementation of CRISPR/Cas-technology to routine model
generation
• Generation of knock-in- and conditional knock-out alleles
• Tailoring and refining existing humanized mouse models
Jochen Welcker, Senior Manager Scientific
Development, Taconic Biosciences
3.30 A CRISPR Way for Drug Discovery
• Harnessing CRISPR technology for target validation and for identifying target of
compound
Yi Yang, Senior Research Investigator, Novartis
4.00 Afternoon Refreshments
Advances in Genome Editing Technologies for Precision Gene Therapy
4.30 Developing a Combination of Genome Editing
Technologies to Enhance Application Specific Genetic
Engineering
• Understand the advantages and disadvantages of the different nuclease platforms
that are currently available and what criteria one might use to choose
• Opportunities and challenges present in translating genome editing to future
therapeutics
Matthew Porteus, Associate Professor of Paediatrics,
Stanford University
5.00 Alpha-1 Antitrypsin Deficiency Liver Disease: Genome
Editing for Animal Models and Gene Therapy
• Summary of animal model creation and potential selective advantage of correction
of AAT liver disease
• In vivo proof if concept for gene transfer, gene silencing and genome editing in
AAT liver disease
Using Genome Editing to Create a Knockout Mouse for
Alpha-1 anti Trypsin and Modify Hepatocytes for Stem
Cell Therapy
• Methods developed for knocking out 5 tandem repeats of the serpina1 gene in
mice
• Editing hepatocytes to increase their secretion of alpha 1 antitrypsin
Terence Flotte, Professor, Dean and Provost,
University of Massachusetts Medical School
Christian Mueller, Assistant Professor, Paediatrics,
University of Massachusetts Medical School
5.30 Therapeutic Promoterless Gene Targeting Without
Nucleases
• Provide a general understanding of rAAV-based gene therapeutics including
current successes and limitations in a clinical setting
• Discuss the proof-of-concept studies to support therapeutic application of
promoter less genome editing using rAAV vectors
Mark Kay, Professor of Pediatrics and Genetic,
Stanford University
6.00 Concluding Objectives for CRISPR Community – What’s
on the Horizon?
Eric Rhodes, Chief Technology Officer, Horizon Discovery
6.05 Close of Congress
6.10 Evening Drinks Reception Hosted by Sigma-Aldrich
CONFERENCE DAY TWO - CONTINUED
Thursday 26th February 2015 Keynote Session Interactive Session Networking Session
8. WORKSHOP A
WORKSHOP B
Tel: +1 212 531 5898 Email: info@hansonwade.com
crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing
CRISPR Precision Gene Editing Congress
Boston, USA | 25-27 February 2015
During this 3 hour interactive workshop, you will learn:
• What indications are addressable by current CRISPR technology?
• What platform advancements are necessary to significantly broaden the range of
CRISPR-based therapeutics?
• What are the key safety issues for clinical development of CRISPR technology?
During this 3 hour interactive workshop, you will learn:
• The main challenges surrounding CRISPR specificity
• The latest efforts in the field to define off-target effects of CRISPR-Cas nucleases
• What approaches need to be harnessed to improve CRISPR-Cas nuclease specificities of action
in human cells
Dr. David Bumcrot is Senior Director of Molecular & Cell Biology at Editas Medicine, Inc.
During his 18 year career he has held positions at a number of innovative biotechnology
companies developing novel therapeutic technologies. Prior to Editas, he was a Director of
Research at Alnylam Pharmaceuticals where he worked to advance several novel RNAi-
based drugs into clinical testing.
Workshop Leader
David Bumcrot
Senior Director, Molecular and Cell
Biology
Editas Medicine
Advancing CRISPR Technology into the Clinic
Date: Friday 27th February 2015 | Time: 9.00am – 12.00pm
Exploring Innovative Approaches: Defining and
Improving the Specificities of CRISPR-Cas Nucleases
Date: Friday 27th February 2015 | Time: 1.00pm – 4.00pm
Workshop Leader
Keith Joung
Associate Chief of Pathology for Research and the Jim
and Ann Orr MGH Research Scholar
Massachusetts General Hospital
Associate Professor of Pathology
Harvard University
J. Keith Joung is a leading innovator in the field of genome editing. Dr. Joung has been a pioneer in the development of important
technologies for targeted genome editing and epigenome editing of human cells. He is a scientific co-founder of Editas Medicine, a company
dedicated to the translation of genome editing technologies for therapy of human diseases.
9. SPONSORS
Sigma-Aldrich
Sigma-Aldrich is proud to offer its newest line of genome editing tools,
Sigma CRISPRs, to the global research community. Sigma CRISPRs offer
rapid, reliable and reproducible results – everything you need for gene
editing experiments. Sigma-Aldrich also offers the CRISPR Core Partnership
Program providing scientists and core facilities with world class service
and a diverse portfolio of innovative CRISPR reagents, with the support of
an industry-leading bioinformatics engine. The Cell Design Studio team at
Sigma Aldrich, utilizes CRISPR, ZFN, and shRNA technologies to rapidly and
efficiently generate model cell lines to be used in basic research, cell-based
assays, target validation and much more.
www.sigmaaldrich.com
Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving
science, our mission is to enable our customers to make the world healthier,
cleaner and safer. We help our customers accelerate life Sciences research,
solve complex analytical challenges, improve patient diagnostics and increase
laboratory productivity. Through our four premier brands Thermo Scientific,
Life Technologies, Fisher Scientific and Unity Lab Services we offer an
unmatched combination of innovative technologies, purchasing convenience
and comprehensive support.
www.thermoscientific.com
HOSTING PARTNER
PROGRAM PARTNER
The Jackson Laboratory
The Jackson Laboratory is an independent, nonprofit biomedical research
institution and a National Cancer Institute-designated Cancer Center with
more than 1,500 employees. Headquartered in Bar Harbor, Maine, it has
a facility in Sacramento, Calif., and a new genomic medicine institute in
Farmington, Conn. The Laboratory’s mission is to discover precise genomic
solutions for disease and empower the global biomedical community in the
shared quest to improve human health.
www.jax.org
PROGRAM PARTNER
Tel: +1 212 531 5898 Email: info@hansonwade.com
crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing
CRISPR Precision Gene Editing Congress
Boston, USA | 25-27 February 2015
Horizon Discovery
Horizon Discovery combines long scientific heritage in translational
research with GENESIS™, a precision gene editing platform incorporating
rAAV, CRISPR and ZFN technologies. Horizon supplies genetically-defined
cell lines, gene-editing tools and services, custom cell line generation,
molecular reference standards, and contract research services to
approaching 1,000 academic, clinical and biopharmaceutical organisations.
www.horizondiscovery.com
LEAD PARTNER
10. SPONSORS
Bio-Rad
Bio-Rad Laboratories, Inc. designs, manufactures, and distributes
a broad range of innovative tools and services to the life science
research and clinical diagnostics markets. Founded in 1952, Bio-
Rad has a global team of more than 7,750 employees and serves
more than 100,000 research and industry customers worldwide
through the company’s global network of operations. Throughout
its existence, Bio-Rad has built strong customer relationships that
advance scientific research and development efforts and support
the introduction of new technology used in the growing fields of
genomics, proteomics, drug discovery, food safety, and medical
diagnostics.
www.bio-rad.com
PROGRAM PARTNER
Transposagen
Transposagen is a worldwide leader in genome engineering
technologies and services with applications in therapeutics,
research & drug discovery, bioproduction, clinical genetic testing
and agriculture. Our products and services include Footprint-
Free(tm) Gene Editing, NextGEN(tm) CRISPR, XTN(tm) TALENs,
and custom cell lines, stem cells, and animal models. Our unique
genome engineering capabilities allow for the creation of nearly
any genetic modification in any genome.
www.transposagenbio.com
EXHIBITOR
Taconic
Taconic is a leading provider of life sciences solutions to
researchers worldwide, offering innovative animal models and
scientific services that facilitate in vivo studies and advance drug
discovery. Our solutions enable investigators to obtain reliable data
early in the development cycle - reducing costs, accelerating time-
to-market, and creating a strong competitive advantage.
tONCO(TM) allows easy access to a comprehensive portfolio of
translational rodent models and services covering every stage of
preclinical in vivo oncology research.
www.taconic.com
PROGRAM PARTNER
Tel: +1 212 531 5898 Email: info@hansonwade.com
crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing
CRISPR Precision Gene Editing Congress
Boston, USA | 25-27 February 2015
11. Code:5164
* All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require
payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer.
The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.
Full payment is due on registration. Cancellation and Substitution
Policy: Cancellations must be received in writing. If the cancellation
is received more than 14 days before the conference attendees will
receive a full credit to a future conference. Cancellations received
14 days or less (including the fourteenth day) prior to the conference
will be liable for the full fee. A substitution from the same
organisation can be made at any time.
Changes to Conference & Agenda: Hanson Wade reserves the right
to postpone or cancel an event, to change the location or alter the
advertised speakers. Hanson Wade is not responsible for any loss
or damage or costs incurred as a result of substitution, alteration,
postponement or cancellation of an event for any reason and
including causes beyond its control including without limitation, acts
of God, natural disasters, sabotage, accident, trade or industrial
disputes, terrorism or hostilities.
Data Protection: The personal information shown and/or provided by
you will be held in a database. It may be used to keep you up to date
with developments in your industry. Sometimes your details may be
obtained or made available to third parties for marketing purposes.
If you do not wish your details to be used for this purpose, please
write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor
Gardens, London, SW1W 0AU
Hanson Wade Limited. Registered in England & Wales. Company
No: 6752216
TERMS & CONDITIONS
VENUE AND ACCOMMODATION:
REGISTER
EVENT PRICES
PRICING & VENUE
INDUSTRY*
Package Standard Prices
GOLD PACKAGE:
Conference + 2 Workshops
$3797 (save $200)
SILVER PACKAGE:
Conference + 1 Workshop
$3198 (save $100)
BRONZE PACKAGE:
Conference Only
$2599
Workshops (each) $699
ACADEMIC*
Package Standard Prices
GOLD PACKAGE:
Conference + 2 Workshops
$2397 (save $200)
SILVER PACKAGE:
Conference + 1 Workshop
$1998 (save $100)
BRONZE PACKAGE:
Conference Only
$1599
Workshops (each) $499
Tel: +1 212 531 5898 Email: info@hansonwade.com
crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing
CRISPR Precision Gene Editing Congress
Boston, USA | 25-27 February 2015
Venue: Located on the Cambridge side of
the Charles River, the newly renovated Royal
Sonesta Boston is a AAA approved Four Diamond
upscale hotel offering guests spectacular city
views, luxury accommodations, regional cuisine,
and contemporary art.
For the traveler looking to experience the best
Boston has to offer, there are many shops,
museums, and historical sites conveniently located
near the Royal Sonesta Boston, known as one
of the best Boston luxury hotels. The hotel also
offers weekday SUV service to the Cambridge area.
Hotel name
Royal Sonesta
40 Edwin Land Boulevard
Cambridge, MA 02142 USA
Accommodation: Overnight
accommodation is not
included in the registration
fee, however accommodation
options will be sent out with
your confirmation email upon
registering.
crispr-congress.com/register
Tel: +1 212 531 5898
Email: register@hansonwade.com
Mail:
Hanson Wade
4th Floor, 52 Grosvenor Gardens,
London, SW1W 0AU
• 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates
Please note that discounts are only valid when
three or more delegates from one company book
and pay at the same time.
TEAM DISCOUNTS*